Weight & Metabolism
Tirzepatide
Choose an option
Select the amount per vial, then choose a package size.
Amount per vial
Package size
Your estimate includes a flat $65 shipping charge and an 8% transaction fee on the product subtotal. No payment is collected here.
Overview
Tirzepatide is a dual GIP/GLP-1 receptor agonist — meaning it activates both the glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors simultaneously. This dual mechanism makes it one of the most potent metabolic research compounds currently under study. FDA-approved as Mounjaro and Zepbound, clinical trials have shown average weight loss of 20-22% of body weight, surpassing semaglutide in head-to-head comparisons.
- Selected variation
- Tirzepatide 100mg
- Amount per vial
- 100mg
- Intended use
- Laboratory research only
- Route of administration
- Subcutaneous injection
Research information
Tirzepatide is a dual agonist for GIP and GLP-1 receptors, functioning as a synthetic incretin mimetic to regulate insulin secretion and glucose levels. It is widely studied for its metabolic effects on weight management and glycemic control. While clinically established for specific conditions, ongoing research into its broader cardio-renal and metabolic benefits remains an active area of investigation.
For laboratory research only. Not for human or animal consumption. Catalog information is not medical advice or a claim of therapeutic benefit.